LIMNW Liminatus Pharma, Inc.

Price Chart

Executive Summary

Liminatus Pharma entered into a warrant inducement agreement whereby an accredited investor exercised approximately 10.3 million existing warrants at a reduced exercise price of $0.18 per share, generating ~$1.86M in gross proceeds. In consideration, the company issued new unregistered warrants covering 20.7 million shares (100% Black-Scholes and 100% Change of Control warrants at $0.18 strike), increasing potential future dilution by up to 20.7 million shares subject to stockholder approval. The company also agreed to pay Maxim Group LLC an 8% cash fee and has a 90-day lock-up on most new equity issuances and a 6-month ban on variable-rate transactions.

Key Financial Metrics

Actionable Insight

Key Facts

• Existing warrants for 10,344,000 shares of common stock were exercised at a reduced exercise price of $0.18 per share.
• Gross proceeds from the exercise are approximately $1,861,920, before deducting financial advisory fees of up to 8%.
• The holder received new unregistered warrants to purchase up to an aggregate of 20,688,000 shares of common stock at $0.18 per share (10,344,000 New Black-Scholes Warrants; 10,344,000 New Change of Control Warrants).
• The new warrants are not exercisable until stockholder approval is obtained (Nasdaq Stockholder Approval) and have a 5-year term from the approval date.
• Proceeds will be used for working capital and general corporate purposes.
• The company agreed to file a resale registration statement on Form S-3 for the New Warrant Shares within 20 calendar days of closing, with effectiveness targeted within 50-90 calendar days.
• A 90-day lock-up on most new equity issuances (exempt issuances excepted) and a 6-month ban on variable-rate transactions apply from the closing date.
• The waiving of the 180-day lock-up from the February 2026 securities purchase agreement allowed this transaction to proceed.

Financial Impact

Immediate cash inflow of ~$1.86M ($1.72M net of estimated 8% advisory fee) against potential future dilution of up to 20.7M shares (exercisable only after stockholder approval). Exercise of existing warrants at $0.18/share represents a fixed cash raise; new warrants represent contingent equity dilution at a fixed strike.

Risk Factors

• Potential future dilution of up to 20.7 million shares from new warrants if stockholder approval is obtained, representing significant overhang.
• Stockholder approval may not be obtained within 90 days or at all, extending uncertainty and potential drag on stock price.
• Cash proceeds of only ~$1.86M provide limited runway for a clinical-stage biopharmaceutical company, likely necessitating additional financing within the next 12 months.
• The 8% cash advisory fee to Maxim Group LLC reduces net proceeds to approximately $1.71M.

Market Snapshot

Documents Analyzed

This report is based on 8 SEC documents filed with EDGAR.

US Market Status

Related Tickers